Eco Animal Regulatory News (EAH)

ECO Animal Health Group plc

("ECO" or the "Company")

Publication of Notice of General Meeting

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it is today publishing a notice of general meeting (the "Notice") to be held on 19 March 2024 to seek shareholders' approval for the board to make limited on market purchases of the Company's ordinary shares of 5 pence each ("Ordinary Shares").

On 8 January 2024, the Company announced the disposal of certain freehold properties and the board stated that it intends to use the majority of the proceeds to advance the growth aspirations of ECO. Assuming the necessary resolution is passed, the Board also intends to use some of the proceeds to purchase Ordinary Shares in the market to cover possible future vesting of employee share-based incentives including share options, long term incentive plans and the deferred bonus scheme.

The Notice will be available shortly on the Company's website at www.ecoanimalhealth.com.

For further information please contact:

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com